Original Article

Vol. 15 No. 1 (2019): The Journal of International Advanced Otology

Predictive Role of Ki-67 and Proliferative-Cell Nuclear Antigen (PCNA) in Recurrent Cholesteatoma

Main Article Content

Ela Araz Server
Çiğdem Kalaycık Ertugay
Sevim Baykal Koca
Ecem Sevim Longur
Özgür Yiğit
Hasan Demirhan
Yasemin Çakır

Abstract

Abstract


 



OBJECTIVES: To investigate the potential use of Ki-67 and pronuclear cell antigen (PCNA) as indicators of recurrent cholesteatoma.



 



MATERIAL and METHODS: Patients who had been diagnosed with cholesteatoma and who had undergone canal wall-down mastoidectomy were included in this study. Subjects were divided into two groups: recurrent and non-recurrent (i.e., cases without recurrence for at least 2 years). Ossicular pathologies were recorded. Histopathologic specimens were stained for Ki-67 and PCNA and the percentages of stained cells were calculated.



 



RESULTS: Neither group demonstrated a significant difference in terms of total Ki-67 per cell, Ki-67-stained cell counts, Ki-67-staining percentages, total PCNA per cell, PCNA-stained cell counts, or PCNA-staining percentages (p>0.05). No significant relationship was noted between the staining percentages for either Ki-67 or PCNA and the incudostapedial involvement (p>0.05); however, a significant relationship was noted between Ki-67 staining and malleus involvement (p<0.05).



 



CONCLUSION: Although the recurrent and non-recurrent cholesteatoma groups showed no significant differences in terms of the percentages of stained cells for either Ki-67 or PCNA, we detected high Ki-67 staining in the malleus involvement group. We concluded that cell-proliferation markers could not be defined as indicators of recurrence of cholesteatoma, but they could be defined as indicators of destructive patterns of this disease.



 



Cite this article as: Araz Server E, Kalaycık Ertugay Ç, Baykal Koca S, Longur ES, Yiğit Ö, Demirhan H, et al. Predictive Role of Ki-67 and Proliferative-Cell Nuclear Antigen (PCNA) in Recurrent Cholesteatoma. J Int Adv Otol 2019; 15(1): 38-42.

Article Details